cGMP-Aligned · FDA-Registered U.S. Facility · Third-Party COA on Every LotSupplied for Research Use Only
BioRegenEx · Research

MSC Exosomes for Autoimmune Conditions | BioRegenEx

← Back to Research Library

Autoimmune diseases affect over 23 million Americans. MSC-derived exosomes offer a novel immunomodulatory approach — delivering anti-inflammatory signals without the systemic risks of conventional immunosuppressants. BioRegenEx supplies FDA-registered, research-grade MSC exosomes exclusively to licensed physicians and regenerative medicine practices.

✓ Peer-Reviewed Research    ✓ Immunomodulatory Mechanism    ✓ Physician Access Only

The Immunomodulatory Challenge in Autoimmune Disease

Autoimmune conditions — ranging from rheumatoid arthritis and lupus to multiple sclerosis and Crohn’s disease — arise when the immune system incorrectly targets the body’s own tissues. Conventional treatments typically rely on broad immunosuppression, which reduces symptoms but carries significant infection risk and does not address the underlying immune dysregulation.

MSC-derived exosomes modulate immune cell behavior — shifting macrophages from pro-inflammatory M1 to anti-inflammatory M2 phenotypes, reducing T-helper 17 (Th17) activity, and expanding regulatory T-cells (Tregs).

What the Research Shows

Rheumatoid Arthritis

A 2023 study in Stem Cell Research & Therapy demonstrated MSC-derived exosomes significantly reduced synovial inflammation and cartilage destruction, with exosomal miRNA payload including miR-let-7b and miR-21 associated with suppression of TNF-α and IL-6 signaling.

Multiple Sclerosis

Research in Frontiers in Immunology (2022) showed intranasally administered MSC exosomes crossed the blood-brain barrier and promoted remyelination, reducing microglial activation and increasing oligodendrocyte precursor proliferation.

Lupus (SLE)

Preclinical data shows MSC-derived exosomes reduce anti-dsDNA antibody titers, renal inflammation, and disease activity scores via upregulation of Tregs and downregulation of Th17 cells.

Mechanism of Immunomodulation

BioRegenEx MSC exosomes carry regulatory miRNAs (miR-21, miR-146a, miR-155), anti-inflammatory proteins (TGF-β, IL-10, PGE2 precursors), surface markers (CD73, CD105), and heat shock proteins that modulate NF-κB, TLR signaling, and cytokine production.

Conditions Under Active Investigation

  • Rheumatoid arthritis (RA)
  • Systemic lupus erythematosus (SLE)
  • Multiple sclerosis (MS)
  • Inflammatory bowel disease
  • Type 1 diabetes
  • Psoriasis and psoriatic arthritis
  • Sjögren’s syndrome
  • Ankylosing spondylitis

Important Regulatory Notice

MSC-derived exosomes are not FDA-approved treatments for autoimmune conditions. All clinical applications must be performed under physician supervision in compliance with applicable FDA guidance. BioRegenEx exosomes are supplied for research and physician-administered use only.

Access for Licensed Physicians

BioRegenEx provides cryopreserved, FDA-registered MSC exosomes to licensed physicians, regenerative medicine clinics, and research institutions. Our exosomes are characterized by NTA, TEM, and Western blot.

Apply for Physician Access →

Supporting Research & Related Applications

📚 Browse the MSC Exosome Research Library (102+ studies) →

Sourcing MSC exosomes for your practice? Partner with BioRegenEx →

Research-use-only. Not intended to diagnose, treat, cure, or prevent any disease.

Frequently Asked Questions

What are MSC-derived exosomes?

Mesenchymal stem cell (MSC)-derived exosomes are nanoscale extracellular vesicles (roughly 30–150 nm) that carry signaling cargo such as proteins, lipids, and microRNA. They are cell-free (acellular) — not stem cells — and are studied in research for their role in cell-to-cell communication. BioRegenEx supplies characterized, research-use-only MSC exosomes with per-lot documentation.

What does research explore about MSC exosomes and autoimmune/immune conditions?

MSC-derived exosomes have been studied in preclinical research for their role in immunomodulation and inflammatory signaling — including models of autoimmune and inflammatory disease. This is early research, not proof of clinical benefit. The published literature is indexed in our Exosome Research Library.

Are MSC exosomes an approved autoimmune treatment?

No. MSC-derived exosomes are not FDA-approved for autoimmune disease or any condition and are supplied for research use only (RUO).

Provided for research and educational purposes. Materials are research-use-only and are not intended to diagnose, treat, cure, or prevent any disease.

Important Information

These statements have not been evaluated by the U.S. Food and Drug Administration. BioRegenEx products are not intended to diagnose, treat, cure, or prevent any disease.

Exosome therapy is an emerging regenerative approach. It is investigational, outcomes vary, and individual results cannot be guaranteed. Patient testimonials reflect individual experiences and are not representative of typical results.

References to regulatory standards — including Section 351(a) of the Public Health Service Act — describe the company’s stated quality and compliance approach and should not be interpreted as FDA approval or endorsement of any product.

This presentation is provided for educational and informational purposes only and does not constitute medical advice. Treatment decisions should always be made in consultation with a qualified, licensed healthcare provider.